<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34560374</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-1298</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>7-8</Issue><PubDate><Year>2021</Year><Season>Sep-Nov</Season></PubDate></JournalIssue><Title>European journal of cell biology</Title><ISOAbbreviation>Eur J Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Inhibition of extracellular regulated kinase (ERK)-1/2 signaling pathway in the prevention of ALS: Target inhibitors and influences on neurological dysfunctions.</ArticleTitle><Pagination><StartPage>151179</StartPage><MedlinePgn>151179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejcb.2021.151179</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0171-9335(21)00030-3</ELocationID><Abstract><AbstractText>Cell signal transduction pathways are essential modulators of several physiological and pathological processes in the brain. During overactivation, these signaling processes may lead to disease progression. Abnormal protein kinase activation is associated with several biological dysfunctions that facilitate neurodegeneration under different biological conditions. As a result, these signaling pathways are essential in understanding brain disorders' development or progression. Recent research findings indicate the crucial role of extracellular signal-regulated kinase-1/2 (ERK-1/2) signaling during the neuronal development process. ERK-1/2 is a key component of its mitogen-activated protein kinase (MAPK) group, controlling certain neurological activities by regulating metabolic pathways, cell proliferation, differentiation, and apoptosis. ERK-1/2 also influences neuronal elastic properties, nerve growth, and neurological and cognitive processing during brain injuries. The primary goal of this review is to elucidate the activation of ERK1/2 signaling, which is involved in the development of several ALS-related neuropathological dysfunctions. ALS is a rare neurological disorder category that mainly affects the nerve cells responsible for regulating voluntary muscle activity. ALS is progressive, which means that the symptoms are getting worse over time, and there is no cure for ALS and no effective treatment to avoid or reverse. Genetic abnormalities, oligodendrocyte degradation, glial overactivation, and immune deregulation are associated with ALS progression. Furthermore, the current review also identifies ERK-1/2 signaling inhibitors that can promote neuroprotection and neurotrophic effects against the clinical-pathological presentation of ALS. As a result, in the future, the potential ERK-1/2 signaling inhibitors could be used in the treatment of ALS and related neurocomplications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sahu</LastName><ForeName>Rakesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Upadhayay</LastName><ForeName>Shubham</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehan</LastName><ForeName>Sidharth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India. Electronic address: sidh.mehan@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cell Biol</MedlineTA><NlmUniqueID>7906240</NlmUniqueID><ISSNLinking>0171-9335</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Demyelination</Keyword><Keyword MajorTopicYN="N">ERK-1/2</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>24</Day><Hour>20</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34560374</ArticleId><ArticleId IdType="doi">10.1016/j.ejcb.2021.151179</ArticleId><ArticleId IdType="pii">S0171-9335(21)00030-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>